13F Pro Quality Score

10.9/100

Rank #2,908 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

9.2/100

Profitability

5.9/100

Balance Sheet

4.6/100

Earnings Quality

4.7/100

Free Cash Flow

4.2/100

Institutional Flow

59.9/100

Revenue Scale

12.2/100

Dilution Risk

2.6/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ALEC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Alector, Inc. (ALEC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALEC at 10.9/100 on a 32-signal composite quality model, placing it at rank #2,908 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (4.2) and balance sheet strength (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Alector, Inc. reports quarterly revenue of $3.3M, net income of $-23.0M, free cash flow of $-34.2M. Top institutional holders of ALEC by reported 13-F value include TCG Crossover Management, BlackRock, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. ALEC trades on the Nasdaq exchange and files with the SEC under CIK 1653087. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALEC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alector, Inc. directly from SEC EDGAR. Alector, Inc.'s 13F Pro composite quality score has ranged between 6 and 72 since 2021, currently 10.9 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

Fun facts about Alector, Inc.

Quirks, history, and lore behind ALEC — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the heart of biotech country.
  • 2
    The Numbers
    Like most clinical-stage biotechs, it carries little to no product revenue and burns cash on R&D — its pipeline is the balance sheet, and hope is the business model.
  • 3
    The History
    Founded in 2013, the company was built around a bold hypothesis: that the immune system — not just neurons — is the key to unlocking treatments for neurodegenerative diseases.
  • 4
    The Secret
    Its entire scientific identity is built on a field called immuno-neurology — using the brain's own immune cells (microglia) as the therapeutic lever against diseases like Alzheimer's and FTD.
  • 5
    The Lore
    It landed a major collaboration deal with GlaxoSmithKline worth up to hundreds of millions, giving a small biotech rare big-pharma validation for its microglial approach.
  • 6
    The Giveaway
    Its ticker is a nod to its name, its science targets Alzheimer's and frontotemporal dementia via the immune system, and its name sounds like it's got a brain — and an 'elector' hidden inside it.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$3.3M

Net Income

Q2 2026

$-23.0M

Free Cash Flow

Q2 2026

$-34.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-79.1% YoY
$21.0MFY 2025
FY22 $133.6MFY23 $97.1MFY24 $100.6MFY25 $21.0M

Net Income

-20.1% YoY
$-142.9MFY 2025
FY22 $-133.3MFY23 $-130.4MFY24 $-119.0MFY25 $-142.9M

Operating Income

-7.6% YoY
$-156.0MFY 2025
FY22 $-137.8MFY23 $-151.7MFY24 $-145.0MFY25 $-156.0M

EPS (Diluted)

-13.0% YoY
$-1.39FY 2025
FY22 $-1.62FY23 $-1.56FY24 $-1.23FY25 $-1.39

Total Assets

-37.4% YoY
$293.2MFY 2025
FY22 $787.6MFY23 $621.8MFY24 $468.3MFY25 $293.2M

Total Debt

+7.3% YoY
$10.7MFY 2025
FY22 FY23 $0.00FY24 $10.0MFY25 $10.7M

Op. Cash Flow

+20.0% YoY
$-184.0MFY 2025
FY22 $-20.3MFY23 $-184.2MFY24 $-229.9MFY25 $-184.0M

Free Cash Flow

+20.4% YoY
$-184.1MFY 2025
FY22 $-24.4MFY23 $-186.5MFY24 $-231.2MFY25 $-184.1M

Get alerted when ALEC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alector, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of ALEC

Companies Similar to ALEC

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TRDA

Entrada Therapeutics, Inc.

8
AI score
Very similar · 8 shared holders
STRO

SUTRO BIOPHARMA, INC.

13
AI score
Very similar · 7 shared holders
SLN

Silence Therapeutics plc

10
AI score
Very similar · 6 shared holders
NRIX

Nurix Therapeutics, Inc.

9
AI score
Similar quality profile · 8 shared holders
EQ

Equillium, Inc.

11
AI score
Similar quality profile · 6 shared holders
ENTA

ENANTA PHARMACEUTICALS INC

17
AI score
Similar quality profile · 3 shared holders
PSNL

Personalis, Inc.

12
AI score
Similar quality profile · 5 shared holders
CTMX

CytomX Therapeutics, Inc.

9
AI score
Similar quality profile · 8 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put ALEC on your watchlist

Track score changes the day Alector, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is ALEC a good stock to buy?

13F Pro's AI-powered analysis of Alector, Inc. (ALEC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALEC are available on the ALEC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALEC is classified as a small company.

Which hedge funds own ALEC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALEC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alector, Inc.'s investment landscape.